 Home > Medical News > Latest Medical News > The first NSCLC adjuvant therapy immunotherapy!

The first NSCLC adjuvant therapy immunotherapy!

 Last Update: 2021-11-01
 Source: Internet
 Author: User

Tags

prism data analysis

different types foreskin

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On October 15, Roche announced that atezolizumab (Tecentriq®) has been approved for adjuvant treatment indications for adult patients with stage II-IIIA NSCLC whose tumors express PD-L1 ≥ 1% after surgery and platinum-based chemotherapy.

From: Roche official website

Today, the new battlefield of tumor immunotherapy has shifted from the capture of large cancer species to more front-line treatments

The approval of Tecentriq is based on the interim analysis results of the Phase III IMpower010 study

Tecentriq has previously shown clinically significant benefits in various types of lung cancer

Although Roche’s Tecentriq lags behind the PD-(L)1 track star drugs Keytruda and Opdivo in terms of sales, Roche has formulated an extensive development plan for Tecentriq, including different cancer types, combination therapies, and the number of treatment lines.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.